BiotechTube

Daclizumab

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing-Remitting Multiple Sclerosis (RRMS)

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS)

Trial Timeline

Apr 18, 2017 → Sep 12, 2018

NCT ID
NCT02881567

About Daclizumab

Daclizumab is a phase 3 stage product being developed by AbbVie for Relapsing-Remitting Multiple Sclerosis (RRMS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02881567. Target conditions include Relapsing-Remitting Multiple Sclerosis (RRMS).

What happened to similar drugs?

20 of 20 similar drugs in Relapsing-Remitting Multiple Sclerosis (RRMS) were approved

Approved (20) Terminated (4) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Ofatumumab + Disease modifying treatment (DMT)NovartisApproved
✅fingolimodNovartisApproved
✅FingolimodNovartisApproved
✅fingolimodNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02881567Phase 3Terminated

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis (RRMS)

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Interferon beta 1aMerckPre-clinical
26
Cladribine 10 mg oral tabletMerckApproved
39
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + TecfideraMerckPhase 2
27
Minocycline + PlaceboMerckPhase 2
27